A. Keith Stewart, MB ChB

home / authors / a-keith-stewart-mb-chb

Articles

Final Thoughts on Case Study and Treating Multiple Myeloma

Joseph Mikhael, MD;Elisabet E. Manasanch, MD;A. Keith Stewart, MB ChB;Sikander Ailawadhi, MD

January 12th 2023

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.

Clinical Trials in R/R Multiple Myeloma

Joseph Mikhael, MD;Elisabet E. Manasanch, MD;A. Keith Stewart, MB ChB;Sikander Ailawadhi, MD

January 12th 2023

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Treatment Options in Early Relapse Multiple Myeloma

Joseph Mikhael, MD;Elisabet E. Manasanch, MD;A. Keith Stewart, MB ChB;Sikander Ailawadhi, MD

January 5th 2023

Dr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.

Case Study: Myeloma at Early Relapse

Joseph Mikhael, MD;Elisabet E. Manasanch, MD;A. Keith Stewart, MB ChB;Sikander Ailawadhi, MD

January 5th 2023

Dr Joseph Mikhael and expert panel review a case study in early relapse multiple myeloma and the impact of cytogenetics in risk assessment for patients with early relapse multiple myeloma.

Frontline Therapy in Multiple Myeloma

Joseph Mikhael, MD;Elisabet E. Manasanch, MD;A. Keith Stewart, MB ChB;Sikander Ailawadhi, MD

December 22nd 2022

Joseph Mikhael, MD, discusses diagnosis criteria and treatment considerations for patients with multiple myeloma in the frontline setting.

Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients

A. Keith Stewart, MB ChB

January 20th 2015

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Dr. Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial

A. Keith Stewart, MB ChB

December 6th 2014

A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.